Table 2. Summary of the Seroconversion (SC) Rates and Geometric Mean Titers (GMT) in Published Studies after 1 or 2 Doses of MMRV Vaccine.
| Study authors and journal [level of evidence] | Countries | # doses, N recd MMRV | Previous MMR, V | MMRV* schedule, N | Timing of tests | Measles | Mumps | Rubella | Varicella | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| %SC | GMT | %SC | GMT | %SC | GMT | %SC | GMT | ||||||
| Nolan et al. Vaccine Dec 2002 (11) [II-2 (fair)] |
Australia | 1 dose N=79 |
Nil | 12 mos. | Post | 98 | 2,964 | 97 | 1,212 | 98 | 57.3 | 93 | 53.9 |
| Knuf et al. Pediatr Infect Dis J Jan 2006 (12) [II-2 (good)] |
Germany, Austria | 2 doses N=311 |
Nil | 12 mos. and 6 wks. later | Post-2 only | 100 | 6,103.9 | 98 | 1,465.4 | 100 | 101.5 | 100 | 4,932.1 |
| Vesikari et al. Pediatr Infect Dis J Feb 2007 (13) [II-2 (good)] |
Finland | 2 doses N=48 |
Nil | 1 to 2 yrs. and 5 to 6 yrs. | Pre-2 Post-2 |
98 100 |
1,694 2,091 |
83 98 |
676 1,534 |
100 100 |
30 100 |
85 100 |
161 1,585 |
| Goh et al. Infection May 2007 (14) [II-2 (good)] |
Singapore | 2 doses N=134 |
Nil | 9 mos. and | Post-1 | 93 | 2,907.7 | 85 | 977.8 | 100 | 64 | 100 | 406.4 |
| 12 mos. | Post-2 | 100 | 4,199.7 | 100 | 2,140.7 | 100 | 98 | 100 | 4,074.7 | ||||
| Zepp et al. Eur J Pediatr Aug 2007 (15) [II-2 (good)] |
Germany | 1 dose N=451 |
Nil | 12-23 mos. | Post-MMRV CoAdmin** |
97.1 95.1 |
4,419.2 3,441.8 |
80.1 80.3 |
916.4 923.3 |
100 99.3 |
53.5 48.1 |
100 98.5 |
316.0 288.6 |
| Schuster et al. Pediatr Infect Dis J Aug 2008 (9) [II-2 (good)] |
Germany | 2 doses N=732 |
Nil | 10–21 mos. & 6 wks. later | Pre-2 Post-2 |
94.5 98.3 |
2,584.7 3,755.9 |
96.1 99.4 |
157.9 589.4 |
99.7 99.7 |
62.9 122.6 |
95.5 99.7 |
80.4 1,903.3 |
| Gillet et al. Vaccine Jan 2009 (16) [II-2 (good)] |
France, Germany, Italy |
1 dose followed by 1 dose V 6–8 wks. Later Total N=197 | MMR ≥ 6 wks. previously (exact age unspecified) | 15 mos.–2 yrs. N=88 (varies with vaccine Ag) | Pre-MMRV Post-MMRV Post-V |
87.5 98.9 - |
1,485.5 2,428.1 - |
92 100 - |
927.2 5,662.7 - |
96.6 100 - |
92.7 122.9 - |
4.6 97.6 100 |
- 93.2 1,312.4 |
| 2 to 6 yrs. N=107 (varies with vaccine Ag) | Pre-MMRV Post-MMRV Post-V |
95.3 100 - |
1,811.5 2,833.0 - |
92.5 100 - |
1,348.5 6,603.7 - |
99.1 100 - |
90.4 165.7 - |
11.2 97.9 100 |
- 88.2 1,109.6 |
||||
| Halperin et al. Vaccine May 2009 (17) [II-2 (good)] |
Canada, Italy, Belgium |
1 dose N=195 |
MMR+V at 12 mos. | 15–75 mos. (med=54 mos.) |
Pre Post |
96.4 100 |
1,872.2 2,375.3 |
94.3 100 |
1,381.4 3,940.9 |
99.5 100 |
86.0 159.4 |
97.9 100 |
93.2 2,532.7 |
* Only MMRV groups are included in this table; please refer to the original studies for the results in the control groups. ** CoAdmin group = MMRV and DTaP-IPV-HBV-Hib given concurrently. Seroconversion (or seropositive for pre-vaccination titer) is as defined by the authors. Please refer to the original publications for the 95% confidence intervals (CI) for SC and GMT, and comparisons with the respective control groups. Note that GMTs are comparable within each study, and should not be compared between studies. mos. = months of age; yrs. = years of age; wks. = weeks between doses; V = univalent varicella vaccine; recd .= received